Engineering Cellular Biosensors with Customizable Antiviral Responses Targeting Hepatitis B Virus.
Bioengineering
Immunity
Viral Microbiology
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
27 Mar 2020
27 Mar 2020
Historique:
received:
30
07
2019
revised:
16
12
2019
accepted:
22
01
2020
pubmed:
28
2
2020
medline:
28
2
2020
entrez:
28
2
2020
Statut:
ppublish
Résumé
SynNotch receptor technology is a versatile tool that uses the regulatory notch core portion with an extracellular scFv and an intracellular transcription factor that enables to program customized input and output functions in mammalian cells. In this study, we designed a novel synNotch receptor comprising scFv against HBs antigen linked with an intracellular artificial transcription factor and exploited it for viral sensing and cellular immunotherapy. The synNotch receptor expressing cells sensed HBV particles and membrane-bound HBs antigens and responded by expressing reporter molecules, secNL or GFP. We also programmed these cells to dispense antiviral responses such as type I interferon and anti-HBV neutralizing mouse-human chimeric antibodies. Our data reveal that synNotch receptor signaling works for membrane-bound ligands such as enveloped viral particles and proteins borne on liposomal vesicles. This study establishes the concepts of "engineered immunity" where the synNotch platform is utilized for cellular immunotherapy against viral infections.
Identifiants
pubmed: 32105634
pii: S2589-0042(20)30050-X
doi: 10.1016/j.isci.2020.100867
pmc: PMC7113479
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100867Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Interests The authors declare no competing interests.
Références
Nat Chem Biol. 2017 Jan 19;13(2):131-132
pubmed: 28103225
Cell. 2010 Mar 19;140(6):805-20
pubmed: 20303872
Nat Rev Immunol. 2002 Sep;2(9):706-13
pubmed: 12209139
Stem Cells. 2017 Jan;35(1):42-50
pubmed: 27641427
Cell. 2016 Feb 11;164(4):780-91
pubmed: 26830878
Mol Ther. 2012 Jan;20(1):46-53
pubmed: 21934654
Clin Liver Dis. 2019 Aug;23(3):383-399
pubmed: 31266615
Sci Transl Med. 2017 Jan 18;9(373):
pubmed: 28100832
Gastroenterology. 2018 May;154(6):1778-1790
pubmed: 29408639
J Gen Virol. 2001 May;82(Pt 5):1013-1025
pubmed: 11297676
Nat Rev Immunol. 2006 Mar;6(3):231-43
pubmed: 16498452
Elife. 2017 Sep 26;6:
pubmed: 28949917
PLoS One. 2017 Nov 29;12(11):e0188923
pubmed: 29186192
Development. 2000 Apr;127(7):1373-85
pubmed: 10704384
Gastroenterology. 2018 May;154(6):1791-1804.e22
pubmed: 29410097
Antiviral Res. 2015 Nov;123:132-7
pubmed: 26408354
Nat Chem Biol. 2017 Feb;13(2):202-209
pubmed: 27941759
Liver Int. 2011 Jan;31 Suppl 1:104-10
pubmed: 21205146
Curr Opin Virol. 2018 Jun;30:9-17
pubmed: 29444493
Biotechnol Adv. 2019 Nov 1;37(6):107393
pubmed: 31051208
Sci Rep. 2019 May 3;9(1):6895
pubmed: 31053795
Cancer Sci. 2015 Nov;106(11):1616-24
pubmed: 26310603
Elife. 2012 Nov 13;1:e00049
pubmed: 23150796
Sensors (Basel). 2017 Jul 13;17(7):
pubmed: 28703749
Virus Res. 2004 Dec;106(2):199-209
pubmed: 15567498
Sci Rep. 2016 Feb 18;6:21240
pubmed: 26888694
Viruses. 2011 Jun;3(6):920-40
pubmed: 21994762
Oncotarget. 2018 May 4;9(34):23681-23694
pubmed: 29805766
World J Gastroenterol. 2016 Oct 28;22(40):8862-8868
pubmed: 27833377
Sci Transl Med. 2013 Apr 3;5(179):179ps7
pubmed: 23552369
Nat Rev Immunol. 2005 Mar;5(3):215-29
pubmed: 15738952
BMC Gastroenterol. 2019 Apr 16;19(1):53
pubmed: 30991954
Cell Rep. 2017 Sep 12;20(11):2639-2653
pubmed: 28903044
Virology. 2017 Sep;509:67-70
pubmed: 28605637
Virus Res. 2018 Jan 2;243:69-74
pubmed: 29074234
Front Immunol. 2018 Jun 01;9:1230
pubmed: 29910816
Nat Biotechnol. 2019 May;37(5):531-539
pubmed: 30886438